Dr. Magliocco to Present at Future Genomics 2023

Dr. Magliocco from Protean will be presenting a special lecture at Future Genomics 2023 on the roles of genomic testing technology for improving the diagnosis and treatment of cancer patients.

Anthony MaglioccoMarch 20, 2023

Dr. Magliocco to Present at ViVE 2023 in Nashville

Dr. Anthony Magliocco, CEO of Protean BioDiagnostics will be presenting at ViVE 2023 in Nashville TN on the topic of how digital solutions are advancing precision oncology.

Anthony MaglioccoMarch 7, 2023

Protean BioDiagnostics Partners with Arima Genomics

Protean BioDiagnostics partners with Arima to make gene fusion testing widely available to patients.

Anthony MaglioccoFebruary 1, 2023

Protean Presents Project DelPHI at AMP 22

Protean presents two case studies this year at AMP 22, on the use of DelPHI, Protean MAPS, and Navify Digital Tools for the timely diagnosis and/or treatment of cancer.

Anthony MaglioccoNovember 1, 2022

Protean Presents on the Importance of Precision Medicine in Uncovering a Patient's True Diagnosis at AMP 22

Protean presents a case study that highlights the ability to catch a liver carcinoma misdiagnosis using pathology review, comprehensive in-house molecular testing, and virtual molecular tumor boards.

Anthony MaglioccoOctober 20, 2022

Protean BioDiagnostics, Inc. Partners with Qualisure Diagnostics, Inc.

Protean BioDiagnostics Enhances Thyroid Cancer Care for Patients with the addition of the Latest Leading Test to its Protean MAPS™ Diagnostic Menu.

Anthony MaglioccoSeptember 6, 2022